Communiqués Newron Pharmaceuticals S.p.A.

Actions

NWRN

IT0004147952

Recherche biotechnologique et médicale

PEA

Temps réel estimé Cboe Europe 09:33:02 08/10/2026			Varia. 5j.	Varia. 1 janv.
5,790 ^CHF	-22,28 %		-26,65 %	-74,84 %

07:50	Newron évalue les motifs de la suspension de ses recheches aux USA	AW
07:39	Newron Pharmaceuticals examine les retours de la FDA américaine sur la suspension de l’essai clinique de son traitement contre la schizophrénie	MT

Communiqués

07:06	Newron Pharmaceuticals S p A : Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program	PU
07:02	Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program	EQ
25/09	Newron Provides Update on Phase 3 ENIGMA-TRS 2 Study	AQ
22/09	Newron presents H1 2026 results and provides corporate update	EQ
22/09	Newron Pharmaceuticals S p A : presents H1 2026 results and provides corporate update	PU
08/09	Newron reports subscription for EUR 5.5 million of shares by investor group as part of up to EUR 38 million total financing to advance Phase 3 evenamide program	EQ
03/09	Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference	AQ
02/09	Newron Pharmaceuticals S p A : announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)	PU
02/09	Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)	EQ
12/08	Newron Pharmaceuticals S.p.A.: Stefan Weber, buy	EQ
12/08	Newron Pharmaceuticals S.p.A.: Prisca Anand, buy	EQ
12/08	Newron Pharmaceuticals S.p.A.: Prisca Anand, buy	EQ
02/07	Newron Provides Update Following Type A Meeting With the FDA	BU
28/05	Newron Pharmaceuticals to Participate in June Investor Conferences	BU
29/04	Newron Pharmaceuticals S p A : reports a pause in enrollment of new study participants in US centers of ENIGMA-TRS 2 study	PU
29/04	Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study	BU
23/04	Newron announces AGM 2026 results	EQ
30/03	Newron Pharmaceuticals S p A : Report (SIRS 2026)	PU
24/03	Newron Presents 2025 Financial Results and Provides 2026 Outlook	BU
24/03	Newron presents 2025 financial results and provides 2026 outlook	EQ
24/03	Newron Pharmaceuticals S p A : presents 2025 financial results and provides 2026 outlook	PU
20/03	Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)	BU
20/03	Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)	EQ
19/03	Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract	BU
19/03	Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract	EQ